<DOC>
	<DOC>NCT01484561</DOC>
	<brief_summary>The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria. The patient must have active disease at both Screening and predose on Day 1 of Period 1. Patient must have had an inadequate response to at least one diseasemodifying antirheumatic drug (DMARD), nonbiologic or biologic, due to ineffectiveness or intolerance. Pregnant or lactating women Serious medical conditions that would make treatment with CP690,550 potentially unsafe. A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidoneiodine, iohexol or other iodinated contrast media.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Phase 1</keyword>
</DOC>